Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease

Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin

(2010) Wolfgang G. Eisert et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Thrombin Inhibition During Kidney Ischemia-Reperfusion Reduces Chronic Graft Inflammation and Tubular Atrophy

(2010) Raphael Thuillier et al.   TRANSPLANTATION

Anti-thrombin Therapy During Warm Ischemia and Cold Preservation Prevents Chronic Kidney Graft Fibrosis in a DCD Model

(2009) F. Favreau et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts

(2009) Galina S. Bogatkevich et al.   ARTHRITIS AND RHEUMATISM

Pulmonary fibrosis: pathogenesis, etiology and regulation

(2009) M S Wilson et al.   Mucosal Immunology

Review: Therapies for interstitial lung disease: past, present and future

(2008) Robert Kim et al.   Therapeutic Advances in Respiratory Disease

Murine models of pulmonary fibrosis

(2007) Bethany B. Moore et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

(2007) Antje Moeller et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY